QUBEC CITY, Aug. 13, 2012 \/PRNewswire\/ - Aeterna Zentaris Inc. (AEZS) (TSX:AEZ) (the\"Company\") today announced that its V.P., Medicinal Chemistry, Matthias Gerlach, PhD, will be making a poster presentation on preclinical results for the Company's novel orally active anticancer PI3K\/Erk 1\/2 inhibitor, AEZS-136, during the 244th National Meeting of the American Chemistry Society which will be held August 19-23, 2012, in Philadelphia. <\/p>\n
About AEZS-136 <\/p>\n
AEZS-136 is an integral part of the Company's kinase research program comprising the investigation of different compounds for single Erk inhibition, single PI3K inhibition and dualErk\/PI3K kinase inhibition. AEZS-136 selectively inhibits the kinase activity of Erk 1\/2 and class 1 PI3Ks, enabling simultaneous inhibition of the Raf-Mek-Erk and the PI3K-Akt signaling cascades. AEZS-136 was discovered using the Company's proprietary compound library and high throughput screening technology. <\/p>\n
About Aeterna Zentaris <\/p>\n
Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. For more information please visit http:\/\/www.aezsinc.com<\/a>.<\/p>\n<\/p>\n More here: QUBEC CITY, Aug. 13, 2012 \/PRNewswire\/ - Aeterna Zentaris Inc Continue reading
\nAeterna Zentaris to Present Preclinical Data for PI3K\/Erk 1\/2 Inhibitor, AEZS-136, at ACS National Meeting<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"